Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
Dry Powder Inhalers have drawn great attention from pharmaceutical scientists in recent years in particular those consisting of low-dose micronized drug particles associated with larger carrier particles and called interactive mixtures. However, there is little understanding of the relation between bulk powder properties such as powder structure and its aerodynamic dispersion performance. The aim of this work was to develop a simple method to measure the air permeability of interactive mixtures used in Dry Powder Inhalers by using Blaine's apparatus--a compendial permeameter and to relate it to the aerodynamic behaviour. The study was done with fluticasone propionate and terbutaline sulphate as drug models that were blended with several lactoses having different particle size distribution thus containing different percentages of fine particle lactose. The quality of the blends was examined by analysing the drug content uniformity. Aerodynamic evaluation of fine particle fraction was obtained using a Twin Stage Impinger. A linear correlation between a bulk property--air permeability of packed powder bed--and the fine particle fraction of drug was observed for the tested drugs. The air permeability reflects the quantity of the free particle fraction in the interparticulate spaces of powder bed that leads to fine particle fraction during fluidization in air flow. A theoretical approach was developed in order to link the air permeability of powder bed and drag force acting on powders during aerosolization process. The permeability technique developed in this study provides a potential tool for screening Dry Powder Inhaler formulations at the development stage.
Le
V N P
VN
College of Pharmacy, Université Lille Nord de France, Lille, France.
Robins
E
E
Flament
M P
MP
D000280:Administration, Inhalation; D000388:Air; D000730:Androstadienes / Q000032:analysis / Q000737:chemistry / Q000493:pharmacokinetics*; D001993:Bronchodilator Agents / Q000032:analysis / Q000737:chemistry / Q000493:pharmacokinetics*; D016503:Drug Delivery Systems; D058995:Dry Powder Inhalers; D005079:Excipients / Q000737:chemistry; D000068298:Fluticasone; D007785:Lactose; D008962:Models, Theoretical; D010316:Particle Size; D010539:Permeability; D011208:Powders / Q000737:chemistry; D013726:Terbutaline / Q000032:analysis / Q000737:chemistry / Q000493:pharmacokinetics*
D000730:Androstadienes; D001993:Bronchodilator Agents; D005079:Excipients; D011208:Powders; D000068298:Fluticasone; D007785:Lactose; D013726:Terbutaline